biotech
biotech Articles
The June 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Published:
NanoViricides made another stride in the fight against COVID-19, and investors have to be happy about it.
Published:
Pfizer is among the current frontrunners for a COVID-19 vaccine, so why is its stock down 13% year to date? And why does one independent research firm say this stock could run much higher?
Published:
After Corvus Pharmaceuticals announced that it would initiate an early-stage immunotherapy study in patients with COVID-19, Wedush sees this stock running much higher.
Published:
Biogen may be on track to be one of the first companies with a meaningful treatment for Alzheimer’s disease, and this could have huge implications for the stock.
Published:
A new research report outlines favorable Liquidia Technologies drug study data that will be presented in the coming weeks, which could add up to more than 300% potential upside.
Published:
Corvus Pharmaceuticals watched the COVID-19 stock bump play out in Tuesday’s session as this company joins the ever-growing list of coronavirus stocks.
Published:
Novavax and Regeneron Pharmaceuticals each made solid progress on Tuesday after each company received a sizable capital injection from the U.S. government’s Operation Warp Speed program.
Published:
24/7 Wall Street has picked out a few of the best and brightest coronavirus stocks that could still see a big push as 2020 continues.
Published:
Here is a look of a few of the biggest clinical trial and FDA updates to watch for in July 2020.
Published:
Akero Therapeutics has been public for only about a year now, and despite shares surging over 30% to an all-time high in Wednesday’s session, analysts think this stock can go much higher.
Published:
Some small companies are destined to be small forever. Others can grow into huge companies over time. What will be the story for Aytu BioScience?
Published:
Pfizer and BioNTech have been collaborating to produce a messenger RNA based vaccine for the past few months, and this work is yielding promising results.
Published:
T2 Biosystems solidified its position as a coronavirus stock on Wednesday morning when it announced the launch of its COVID-19 molecular diagnostic test.
Published:
While COVID-19 pandemic is not its only target, that has been the main driver of the interest in Inovio Pharmaceuticals so far in 2020.
Published: